Monday June 10, 16:30–18:30. Room W-3001, Moscone Center, San Francisco, California
- Introduction and study background. Julio Rosenstock, MD
- Study design, statistical plan, and baseline characteristics. Mark Espeland, PhD
- Metabolic and body weight outcomes. Steven E. Kahn, MB, ChB
- Cardiovascular, mortality, and hospitalization outcomes. Nikolaus Marx, MD, FESC, FAHA
- Adverse events and hypoglycemia analyses. Bernard Zinman, CM, MD
- Clinical implications for the cardiologist and diabetologists. Darren K. McGuire, MD, MHSc, Bernard Zinman, CM, MD
- Independent commentator. Matthew C. Riddle, MD
- Final Remarks and acknowledgements. Julio Rosenstock, MD
The diabetes community is anxiously awaiting the results of this cardiovascular outcome trial. As the only active comparator trial, we are hoping to learn more about the use of a sulfonlyurea in high-risk patients when compared to a DPP-4 inhibitor.
More on this trial
- Clinical study overview | CAROLINA trial
- Expert view | The CAROLINA trial: Make or break for sulfonylureas?
- Quick guide | Round-up of the DPP-4 inhibitor CV outcome trials